- Home
- UGRO vs APLM Comparison
UGRO vs APLM Comparison
Compare UGRO & APLM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UGRO
- APLM
- Stock Information
- Founded
- UGRO 2014
- APLM 2016
- Country
- UGRO United States
- APLM United States
- Employees
- UGRO N/A
- APLM N/A
- Industry
- UGRO Industrial Specialties
- APLM Blank Checks
- Sector
- UGRO Consumer Discretionary
- APLM Finance
- Exchange
- UGRO Nasdaq
- APLM Nasdaq
- Market Cap
- UGRO 18.0M
- APLM 15.6M
- IPO Year
- UGRO N/A
- APLM N/A
- Fundamental
- Price
- UGRO $1.43
- APLM $0.10
- Analyst Decision
- UGRO Strong Buy
- APLM Strong Buy
- Analyst Count
- UGRO 2
- APLM 2
- Target Price
- UGRO $5.63
- APLM $4.25
- AVG Volume (30 Days)
- UGRO 41.9K
- APLM 1.2M
- Earning Date
- UGRO 11-22-2024
- APLM 08-14-2024
- Dividend Yield
- UGRO N/A
- APLM N/A
- EPS Growth
- UGRO N/A
- APLM N/A
- EPS
- UGRO N/A
- APLM N/A
- Revenue
- UGRO $70,320,066.00
- APLM $2,101,000.00
- Revenue This Year
- UGRO $14.76
- APLM N/A
- Revenue Next Year
- UGRO $21.29
- APLM N/A
- P/E Ratio
- UGRO N/A
- APLM N/A
- Revenue Growth
- UGRO 12.08
- APLM 70.54
- 52 Week Low
- UGRO $1.02
- APLM $0.08
- 52 Week High
- UGRO $2.84
- APLM $1.23
- Technical
- Relative Strength Index (RSI)
- UGRO 43.12
- APLM 30.56
- Support Level
- UGRO $1.42
- APLM $0.11
- Resistance Level
- UGRO $1.69
- APLM $0.13
- Average True Range (ATR)
- UGRO 0.15
- APLM 0.01
- MACD
- UGRO -0.04
- APLM -0.00
- Stochastic Oscillator
- UGRO 3.92
- APLM 22.27
About UGRO urban-gro Inc.
Urban-gro Inc is an integrated professional services and construction design-build firm. Its business focuses predominantly on providing fee-based knowledge-based services as well as the value-added reselling of equipment. The company offers value-added architectural, engineering, systems procurement and integration, and construction design-build solutions to customers operating in the controlled environment agriculture (CEA) and industrial and other commercial (Commercial) sectors. It derives revenue predominately from the sale of equipment systems, services, construction design-build, and other various immaterial contracts with customers.
About APLM Apollomics Inc.
Apollomics Inc is an innovative clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company lead programs include vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia.